Teijin Limited, Teijin Regenet Co., Ltd., and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. The collaboration aims to advance manufacturing technologies and strengthen Japan’s manufacturing infrastructure for cell and gene therapies, thereby contributing to the broader availability of these innovative treatments.
Cell and gene therapies, including CAR-T cell therapies, are expected to become increasingly important treatment options for cancer and other intractable diseases. In Japan, however, expanding the availability of specialized manufacturing personnel and manufacturing facilities remain significant challenges, underscoring the need for a more robust and sustainable supply framework.
Enhancing CAR-T Cell Therapy with Teijin Regenet
Under the joint research agreement, Shinshu University Hospital’s expertise in CAR-T cell therapy research, development and clinical application will be combined with Teijin Regenet’s manufacturing and quality-management know-how cultivated through its contract development and manufacturing organization (CDMO) business for regenerative medicine products. The partners will work together to enhance manufacturing technologies and strengthen the manufacturing base for cell and gene therapies.
The collaboration will also utilize the Cell Processing Center (CPC) at Shinshu University Hospital to explore future manufacturing automation and efficiency improvements. In addition, the partners will work to accumulate practical knowledge related to quality testing technologies and quality-control methodologies.
Going forward, Teijin, Teijin Regenet and Shinshu University Hospital will leverage the outcomes of this joint research to contribute to the advancement of cell and gene therapies in Japan and help create an environment in which patients can more readily access the treatments they need.
